4.6 Article

Contribution of the Gut Microbiota in P28GST-Mediated Anti-Inflammatory Effects: Experimental and Clinical Insights

Journal

CELLS
Volume 8, Issue 6, Pages -

Publisher

MDPI
DOI: 10.3390/cells8060577

Keywords

helminth protein; immunization; inflammatory bowel diseases; fecal microbiota; fecal transplantation; mice; humans

Categories

Funding

  1. Institut National de la Sante et de la Recherche (Inserm)
  2. Lille University [SF3I]
  3. French National Research Agency via ACROHNEM [ANR-11-RPIB-0021]
  4. North Pas-de-Calais Regional Council
  5. Lille University Hospital (CHU de Lille) [2013-02]
  6. Biotech Society Par'Immune
  7. DigestScience Foundation
  8. FHU IMMINeNT
  9. Agence Nationale de la Recherche (ANR) [ANR-11-RPIB-0021] Funding Source: Agence Nationale de la Recherche (ANR)

Ask authors/readers for more resources

An original immuno-regulatory strategy against inflammatory bowel diseases based on the use of 28 kDa glutathione S-transferase (P28GST), a unique schistosome protein, was recently proposed. Improvement of intestinal inflammation occurs through restoration of the immunological balance between pro-inflammatory T-helper 1 (Th1) responses and both T-helper 2 (Th2) and regulatory responses. However, detailed mechanisms explaining how P28GST prevents colitis and promotes gut homeostasis remain unknown. Considering the complex interplay between the adaptive and innate immune system and the intestinal microbiota, we raised the question of the possible role of the microbial ecosystem in the anti-inflammatory effects mediated by the helminth-derived P28GST protein. We first analyzed, by 16S rRNA sequencing, the bacterial profiles of mice fecal microbiota at several time points of the P28GST-immunomodulation period prior to trinitrobenzene sulfonic acid (TNBS)-colitis. The influence of gut microbiota in the P28GST-mediated anti-inflammatory effects was then assessed by fecal microbiota transplantation experiments from P28GST-immunized mice to either conventional or microbiota depleted naive recipient mice. Finally, the experimental data were supplemented by the temporal fecal microbiota compositions of P28GST-treated Crohn's disease patients from a pilot clinical study (NCT02281916). The P28GST administration slightly modulated the diversity and composition of mouse fecal microbiota while it significantly reduced experimental colitis in mice. Fecal microbiota transplantation experiments failed to restore the P28GST-induced anti-inflammatory effects. In Crohn's disease patients, P28GST also induced slight changes in their overall fecal bacterial composition. Collectively, these results provide key elements in both the anti-inflammatory mechanisms and the safe therapeutic use of immunomodulation with such promising helminth-derived molecules.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Neuroimaging

Clinical outcome of patients with mild pre-stroke morbidity following endovascular treatment: a HERMES substudy

Rosalie McDonough, Johanna M. Ospel, Charles B. L. M. Majoie, Jeffrey L. Saver, Philip White, Diederik W. J. Dippel, Scott B. Brown, Andrew M. Demchuk, Tudor G. Jovin, Peter J. Mitchell, Serge Bracard, Bruce C. Campbell, Keith W. Muir, Michael D. Hill, Francis Guillemin, Mayank Goyal

Summary: This study examined the effect of pre-stroke functional levels on the outcome of endovascular therapy. The results showed that patients with mild pre-existing disability/symptoms had worse outcomes compared to those without disability. However, within the subgroup of patients with mild disability/symptoms, endovascular therapy still had a significant benefit.

JOURNAL OF NEUROINTERVENTIONAL SURGERY (2023)

Article Infectious Diseases

Serum neutralization of SARS coronavirus 2 Omicron sublineages BA.1 and BA.2 and cellular immune responses 3 months after booster vaccination

Enagnon Kazali Alidjinou, Julie Demaret, Benedicte Corroyer-Simovic, Fanny Vuotto, Sophie Miczek, Julien Labreuche, Anne Goffard, Jacques Trauet, Daniela Lupau, Arnaud Dendooven, Dominique Huvent-Grelle, Juliette Podvin, Daniel Dreuil, Karine Faure, Dominique Deplanque, Laurence Bocket, Alain Duhamel, Annie Sobaszek, Didier Hober, Michael Hisbergues, Francois Puisieux, Brigitte Autran, Yazdan Yazdanpanah, Myriam Labalette, Guillaume Lefevre

Summary: The study investigated the serum neutralizing activity and T cell response against BA.1 and BA.2 sublineages before and after the administration of the booster vaccine in healthcare workers. The results showed that a low neutralizing activity was observed before the booster dose, but significant increases in neutralizing antibodies against Delta, BA.1, and BA.2 were observed after 3 months. Participants with recent infection maintained stable neutralizing antibody levels against Delta and BA.2, and showed an increase in neutralizing antibodies against BA.1.

CLINICAL MICROBIOLOGY AND INFECTION (2023)

Article Pharmacology & Pharmacy

In vitro and in vivo evaluation of a pH-, microbiota- and time-based oral delivery platform for colonic release

S. Moutaharrik, A. Maroni, C. Neut, C. Dubuquoy, L. Dubuquoy, A. Foppoli, M. Cerea, L. Palugan, F. Siepmann, J. Siepmann, A. Gazzaniga

Summary: A novel drug delivery system based on multiple drug release triggers was developed and evaluated for oral colon delivery, with a specific focus on inflammatory bowel disease (IBD) therapy. The system demonstrated pulsatile drug release in different release media and faster drug release in simulated colonic fluid with fecal bacteria from IBD patients. Promising results were observed in a preliminary rat study, indicating potential therapeutic effects on colitis progression and microbiota alteration.

EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2023)

Article Pharmacology & Pharmacy

Drug repurposing: From the discovery of a useful pharmacological effect to making the treatment available to the patient

Dominique Deplanque, Christine Fetro, Antoine Ferry, Philippe Lechat, Terence Beghyn, Claude Bernard, Antoine Bernasconi, Hugues Bienayme, Celine Cougoule, Joanie Del Bano, Claire Demiot, Benedicte Lebrun-Vignes

Summary: The repurposing of existing drugs for new indications can address unmet therapeutic needs, especially in the context of rare diseases and emergencies. However, there are challenges in accessing the drug and its data during preclinical and clinical stages, and clinical results may not guarantee marketing authorization or patient care. The round table proposed recommendations to overcome these obstacles, including the establishment of a well-funded public-private partnership to provide individualized support for projects until marketing application.

THERAPIE (2023)

Article Biotechnology & Applied Microbiology

Study of the persistence and dynamics of recombinant mCherry-producing Yarrowia lipolytica strains in the mouse intestine using fluorescence imaging

Catherine Madzak, Sabine Poiret, Sophie Salome Desnoulez, Benoit Foligne, Frank Lafont, Catherine Daniel

Summary: Yarrowia lipolytica is a potential vector for oral delivery of therapeutic proteins. Researchers engineered two strains of Y. lipolytica to produce the model protein mCherry, and found that the strains persisted in the mouse intestine and maintained protein expression for at least 1 week after oral administration. This study suggests that Y. lipolytica strains can be used as oral delivery vectors for therapeutic proteins.

MICROBIAL BIOTECHNOLOGY (2023)

Article Public, Environmental & Occupational Health

Characteristics and outcomes of an international cohort of 600000 hospitalized patients with COVID-19

Christiana Kartsonaki, J. Kenneth Baillie, Noelia Garcia Barrio, Joaquin Baruch, Abigail Beane, Lucille Blumberg, Fernando Bozza, Tessa Broadley, Aidan Burrell, Gail Carson, Barbara Wanjiru Citarella, Andrew Dagens, Emmanuelle A. Dankwa, Christl A. Donnelly, Jake Dunning, Loubna Elotmani, Martina Escher, Nataly Farshait, Jean-Christophe Goffard, Bronner P. Goncalves, Matthew Hall, Madiha Hashmi, Benedict Sim Lim Heng, Antonia Ho, Waasila Jassat, Miguel Pedrera Jimenez, Cedric Laouenan, Samantha Lissauer, Ignacio Martin-Loeches, France Mentre, Laura Merson, Ben Morton, Daniel Munblit, Nikita A. Nekliudov, Alistair D. Nichol, Budha Charan Singh Oinam, David Ong, Prasan Kumar Panda, Michele Petrovic, Mark G. Pritchard, Nagarajan Ramakrishnan, Grazielle Viana Ramos, Claire Roger, Oana Sandulescu, Malcolm G. Semple, Pratima Sharma, Louise Sigfrid, Emily C. Somers, Anca Streinu-Cercel, Fabio Taccone, Pavan Kumar Vecham, Bharath Kumar Tirupakuzhi Vijayaraghavan, Jia Wei, Evert-Jan Wils, Xin Ci Wong, Peter Horby, Amanda Rojek, Piero L. Olliaro, Ali Abbas

Summary: This study analyzed demographic features, treatments, and clinical outcomes of hospitalized COVID-19 patients in 52 countries from January 2020 to January 2022. Age and male sex were associated with a higher risk of death. Symptoms, co-morbidities, and treatments were associated with clinical outcomes. This comprehensive international study provides valuable information for prioritizing treatment for COVID-19 patients at higher risk of death.

INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2023)

Article Immunology

Neutrophil Activation and Immune Thrombosis Profiles Persist in Convalescent COVID-19

Hakim Hocini, Aurelie Wiedemann, Fabiola Blengio, Cecile Lefebvre, Minerva Cervantes-Gonzalez, Emile Foucat, Pascaline Tisserand, Mathieu Surenaud, Severin Coleon, Melanie Prague, Lydia Guillaumat, Corinne Krief, Craig Fenwick, Cedric Laouenan, Lila Bouadma, Jade Ghosn, Giuseppe Pantaleo, Rodolphe Thiebaut, Yves Levy, Laurent Abel, Amal Abrous, Claire Andrejak, Francois Angoulvant, Delphine Bachelet, Marie Bartoli, Sylvie Behilill, Marine Beluze, Krishna Bhavsar, Anissa Chair, Charlotte Charpentier, Leo Chenard, Catherine Chirouze, Sandrine Couffin-cadiergues, Camille Couffignal, Nathalie D. E. Castro, Marie-Pierre Debray, Dominique Deplanque, Diane Descamps, Alpha Diallo, Fernanda Dias D. A. Silva, Celine Dorival, Xavier Duval, Philippine Eloy, Vincent Enouf, Helene Esperou, Marina Esposito-farese, Manuel Etienne, Aline-Marie Florence, Alexandre Gaymard, Tristan Gigante, Morgane Gilg, Francois Goehringer, Jeremie Guedj, Ikram Houas, Isabelle Hoffmann, Jean-Sebastien Hulot, Salma Jaafoura, Simon Jamard, Ouifiya Kafif, Antoine Khalil, Nadhem Lafhej, Samira Laribi, Minh Le, Quentin LE. Hingrat, Soizic LE. Mestre, Sophie Letrou, Bruno Lina, Guillaume Lingas, Denis Malvy, France Mentre, Hugo Mouquet, Nadege Neant, Christelle Paul, Aurelie Papadopoulos, Ventzislava Petrov-sanchez, Gilles Peytavin, Valentine Piquard, Olivier Picone, Manuel Rosa-calatrava, Benedicte Rossignol, Patrick Rossignol, Carine Roy, Marion Schneider, Coralie Tardivon, Jean-Francois Timsit, Sarah Tubiana, Sylvie Van Der Werf, Benoit Visseaux

Summary: This study investigated the immunological dysfunction underlying the persistence of symptoms in individuals after severe COVID-19 infection. The analysis of cytokines, cell phenotypes, antibodies, and gene expression profiles revealed persistent abnormalities even up to 6 months after hospital discharge, including high levels of activation markers, T-cell abnormalities, decreased antibodies, and upregulation of genes related to blood components. These findings suggest the need for extended clinical follow-up and preventive measures for patients.

JOURNAL OF CLINICAL IMMUNOLOGY (2023)

Editorial Material Pharmacology & Pharmacy

Hydroxychloroquine and COVID-19: The endgame!

Dominique Deplanque

THERAPIE (2023)

Article Genetics & Heredity

Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19

Daniela Matuozzo, Estelle Talouarn, Astrid Marchal, Peng Zhang, Jeremy Manry, Yoann Seeleuthner, Yu Zhang, Alexandre Bolze, Matthieu Chaldebas, Baptiste Milisavljevic, Adrian Gervais, Paul Bastard, Takaki Asano, Lucy Bizien, Federica Barzaghi, Hassan Abolhassani, Ahmad Abou Tayoun, Alessandro Aiuti, Ilad Alavi Darazam, Luis M. Allende, Rebeca Alonso-Arias, Andres Augusto Arias, Gokhan Aytekin, Peter Bergman, Simone Bondesan, Yenan T. Bryceson, Ingrid G. Bustos, Oscar Cabrera-Marante, Sheila Carcel, Paola Carrera, Giorgio Casari, Khalil Chaibi, Roger Colobran, Antonio Condino-Neto, Laura E. Covill, Ottavia M. Delmonte, Loubna El Zein, Carlos Flores, Peter K. Gregersen, Marta Gut, Filomeen Haerynck, Rabih Halwani, Selda Hancerli, Lennart Hammarstroem, Nevin Hatipoglu, Adem Karbuz, Sevgi Keles, Christele Kyheng, Rafael Leon-Lopez, Jose Luis Franco, Davood Mansouri, Javier Martinez-Picado, Ozge Metin Akcan, Isabelle Migeotte, Pierre-Emmanuel Morange, Guillaume Morelle, Andrea Martin-Nalda, Giuseppe Novelli, Antonio Novelli, Tayfun Ozcelik, Figen Palabiyik, Qiang Pan-Hammarstroem, Rebeca Perez de Diego, Laura Planas-Serra, Daniel E. Pleguezuelo, Carolina Prando, Aurora Pujol, Luis Felipe Reyes, Jacques G. Riviere, Carlos Rodriguez-Gallego, Julian Rojas, Patrizia Rovere-Querini, Agatha Schlueter, Mohammad Shahrooei, Ali Sobh, Pere Soler-Palacin, Yacine Tandjaoui-Lambiotte, Imran Tipu, Cristina Tresoldi, Jesus Troya, Diederik van de Beek, Mayana Zatz, Pawel Zawadzki, Saleh Zaid Al-Muhsen, Mohammed Faraj Alosaimi, Fahad M. Alsohime, Hagit Baris-Feldman, Manish J. Butte, Stefan N. Constantinescu, Megan A. Cooper, Clifton L. Dalgard, Jacques Fellay, James R. Heath, Yu-Lung Lau, Richard P. Lifton, Tom Maniatis, Trine H. Mogensen, Horst von Bernuth, Alban Lermine, Michel Vidaud, Anne Boland, Jean-Francois Deleuze, Robert Nussbaum, Amanda Kahn-Kirby, France Mentre, Sarah Tubiana, Guy Gorochov, Florence Tubach, Pierre Hausfater, C. O. V. I. D. Human Genetic Effort, Isabelle Meyts, Shen-Ying Zhang, Anne Puel, Luigi D. Notarangelo, Stephanie Boisson-Dupuis, Helen C. Su, Bertrand Boisson, Emmanuelle Jouanguy, Jean-Laurent Casanova, Qian Zhang, Laurent Abel, Aurelie Cobat

Summary: Through a genome-wide rare variant burden association analysis, it was found that there is an association between at-risk variants in the TLR7 gene and rare loss-of-function variants in TLR3-dependent type I interferon immunity genes. These findings suggest that rare variants in TLR3- and TLR7-dependent type I interferon immunity genes may underlie life-threatening COVID-19 in patients under 60 years old.

GENOME MEDICINE (2023)

Article Polymer Science

Injectable Chitosan-Based Hydrogels for Trans-Cinnamaldehyde Delivery in the Treatment of Diabetic Foot Ulcer Infections

Henry Chijcheapaza-Flores, Nicolas Tabary, Feng Chai, Mickael Maton, Jean-Noel Staelens, Frederic Cazaux, Christel Neut, Bernard Martel, Nicolas Blanchemain, Maria Jose Garcia-Fernandez

Summary: This study aims to combine the properties of hydrogels based on chitosan (CHT) and the polymer of beta cyclodextrin (PCD) for local delivery of cinnamaldehyde (CN) in diabetic foot ulcers. The results demonstrated the successful development of a cytocompatible (ISO 10993-5) injectable hydrogel with antibacterial and antibiofilm activity. Furthermore, a partial active molecule release and an increase in hydrogel elasticity were observed in the presence of CN.
Article Biochemistry & Molecular Biology

An extended transcription factor regulatory network controls hepatocyte identity

Julie Dubois-Chevalier, Celine Gheeraert, Alexandre Berthier, Clemence Boulet, Vanessa Dubois, Loic Guille, Marie Fourcot, Guillemette Marot, Karine Gauthier, Laurent Dubuquoy, Bart Staels, Philippe Lefebvre, Jerome Eeckhoute

Summary: Cell identity is controlled by a core transcriptional regulatory circuitry (CoRC) consisting of cell-specific transcription factors (TFs). However, our study reveals that the transcriptional regulatory network regulating hepatocyte identity is more complex than initially thought. We identified a set of TFs, which we call hepatocyte identity (Hep-ID)(CONNECT) TFs, that not only control hepatocyte identity effector genes, but also interact with TFs of the CoRC. Furthermore, we found that Hep-IDCONNECT TFs play a role in fine-tuning CoRC TF expression and can reset CoRC TF expression in dedifferentiated hepatocytes.

EMBO REPORTS (2023)

Article Chemistry, Medicinal

Receptor Interacting Ser/Thr-Protein Kinase 2 as a New Therapeutic Target

Morgane Rivoal, Laurent Dubuquoy, Regis Millet, Natascha Leleu-Chavain

Summary: RIPK2 is an essential downstream signaling molecule that activates various immune receptors, playing a crucial role in the release of pro-inflammatory cytokines. It has emerged as a potential therapeutic target for inflammatory diseases and cancer. This Perspective provides an overview of RIPK2 function, its role in diseases, available inhibitors, therapeutic strategies, and current challenges and outlook.

JOURNAL OF MEDICINAL CHEMISTRY (2023)

Article Multidisciplinary Sciences

Cytomegalovirus in donors for fecal microbiota transplantation, the phantom menace?

Tatiana Galperine, Ilka Engelmann, Sebastien Hantz, Deiborah Postil, Anny Dewilde, Dominique Deplanque, Renaud Martin, Julien Labreuche, Mouna Lazrek, Stephanie Somers, Elodie Ribot, Sophie Alain

Summary: Fecal Microbiota Transplantation (FMT) is the preferred treatment for recurrent Clostridioides difficile Infections (CDI). However, the donor screening process varies between countries and guidelines differ on the need for CMV testing. This study found that healthy donors with positive CMV serology do not shed CMV DNA in their stool, suggesting that CMV screening may not be necessary.

PLOS ONE (2023)

Article Multidisciplinary Sciences

Inborn errors of OAS-RNase L in SARS-CoV-2-related multisystem inflammatory syndrome in children

Danye Lee, Jeremie Le Pen, Ahmad Yatim, Beihua Dong, Yann Aquino, Masato Ogishi, Remi Pescarmona, Estelle Talouarn, Darawan Rinchai, Peng Zhang, Magali Perret, Zhiyong Liu, Iolanda Jordan, Sefika Elmas Bozdemir, Gulsum Iclal Bayhan, Camille Beaufils, Lucy Bizien, Aurelie Bisiaux, Weite Lei, Milena Hasan, Jie Chen, Christina Gaughan, Abhishek Asthana, Valentina Libri, Joseph M. Luna, Fabrice Jaffre, H. -Heinrich Hoffmann, Eleftherios Michailidis, Marion Moreews, Yoann Seeleuthner, Kaya Bilguvar, Shrikant Mane, Carlos Flores, Yu Zhang, Andres A. Arias, Rasheed Bailey, Agatha Schlueter, Baptiste Milisavljevic, Benedetta Bigio, Tom Le Voyer, Marie Materna, Adrian Gervais, Marcela Moncada-Velez, Francesca Pala, Tomi Lazarov, Romain Levy, Anna-Lena Neehus, Jeremie Rosain, Jessica Peel, Yi-Hao Chan, Marie-Paule Morin, Rosa Maria Pino-Ramirez, Serkan Belkaya, Lazaro Lorenzo, Jordi Anton, Selket Delafontaine, Julie Toubiana, Fanny Bajolle, Victoria Furnado, Marta L. DeDiego, Nadhira Fidouh, Flore Rozenberg, Jordi Perez-Tur, Shuibing Chen, Todd Evans, Frederic Geissmann, Pierre Lebon, Susan R. Weiss, Damien Bonnet, Xavier Duval, Qiang Pan-Hammarstroem, Anna M. Planas, Isabelle Meyts, Filomeen Haerynck, Aurora Pujol, Vanessa Sancho-Shimizu, Clifford L. Dalgard, Jacinta Bustamante, Anne Puel, Stephanie Boisson-Dupuis, Bertrand Boisson, Tom Maniatis, Qian Zhang, Paul Bastard, Luigi Notarangelo, Vivien Beziat, Rebeca Perez de Diego, Carlos Rodriguez-Gallego, Helen C. Su, Richard P. Lifton, Emmanuelle Jouanguy, Aurelie Cobat, Laia Alsina, Sevgi Keles, Elie Haddad, Laurent Abel, Alexandre Belot, Lluis Quintana-Murci, Charles M. Rice, Robert H. Silverman, Shen-Ying Zhang, Jean-Laurent Casanova

SCIENCE (2023)

No Data Available